Literature DB >> 2456631

Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA).

W Slikker1, S F Ali, A C Scallet, C H Frith, G D Newport, J R Bailey.   

Abstract

MDMA is an amphetamine analog prescribed by some health professionals in the field of psychotherapy and used as a recreational drug by the general public. In recent reports, investigators have suggested that MDMA produces acute neurotoxicity when administered by subcutaneous injection. In order to determine if MDMA produces lasting neurochemical alterations after oral administration, groups of six rats (adult male Sprague-Dawley) were dosed by gavage with either 40 or 80 mg/kg of MDMA or saline vehicle once every 12 hr for 4 days. These rats were terminated 2 weeks after the first dose along with an additional group of rats (80 mg/kg) terminated 4 weeks after the first dose. Brain regions including the hippocampus (H), caudate nucleus (CN), hypothalamus (HY), frontal cortex (FC), and brain stem (BS) were analyzed by HPLC with electrochemical detection for concentrations of dopamine (DA), dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), serotonin (5-HT), 5-hydroxyindoleacetic acid (5-HIAA), and norepinephrine (NE). In the CN, 40 mg/kg MDMA produced no change in DA, DOPAC, or HVA, but a 50-60% decrease in 5-HT and 5-HIAA concentrations was observed at 2 weeks. Similar effects were observed at 80 mg/kg at both 2 weeks and 4 weeks. A temporary decrease was also seen in DA (21%) and in HVA (34%) 2 weeks but not 4 weeks after the 80 mg/kg dose regimen. In the H, MDMA (40 or 80 mg/kg) produced no change in NE, but a 50-60% decrease was seen in 5-HT and 5-HIAA concentrations at 2 weeks. Concentrations of 5-HT and 5-HIAA were significantly decreased in the HY and FC by all MDMA treatments, but DA and DOPAC concentrations were not altered as compared to vehicle controls. BS was least affected by treatment with no change in DA, DOPAC, or 5-HIAA concentrations and only a slight decrease in 5-HT (19-33%) concentrations at 2 weeks but not at 4 weeks. To determine the sensitivity of the nonhuman primate to MDMA, a total of nine rhesus monkeys were dosed with vehicle or 5 or 10 mg/kg MDMA (n = 3) by gastric intubation twice per day for 4 days. One month after MDMA dosing, a dose-related reduction from vehicle control values for 5-HT and 5-HIAA was observed. These results indicate that the monkey may be more sensitive than the rat to the persistent serotonergic neurotoxicity of MDMA.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2456631     DOI: 10.1016/0041-008x(88)90285-2

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  18 in total

1.  Reduced 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy)-initiated oxidative DNA damage and neurodegeneration in prostaglandin H synthase-1 knockout mice.

Authors:  Winnie Jeng; Peter G Wells
Journal:  ACS Chem Neurosci       Date:  2010-02-23       Impact factor: 4.418

2.  Impact of ambient temperature on hyperthermia induced by (+/-)3,4-methylenedioxymethamphetamine in rhesus macaques.

Authors:  Stefani N Von Huben; Christopher C Lay; Rebecca D Crean; Sophia A Davis; Simon N Katner; Michael A Taffe
Journal:  Neuropsychopharmacology       Date:  2006-04-12       Impact factor: 7.853

3.  Alterations in the levels of monoamines in discrete brain regions of clomipramine-induced animal model of endogenous depression.

Authors:  M Vijayakumar; B L Meti
Journal:  Neurochem Res       Date:  1999-03       Impact factor: 3.996

4.  3,4-methylenedioxymethamphetamine (ecstasy)-induced learning and memory impairments depend on the age of exposure during early development.

Authors:  H W Broening; L L Morford; S L Inman-Wood; M Fukumura; C V Vorhees
Journal:  J Neurosci       Date:  2001-05-01       Impact factor: 6.167

Review 5.  Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy').

Authors:  U D McCann; S O Slate; G A Ricaurte
Journal:  Drug Saf       Date:  1996-08       Impact factor: 5.606

6.  Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery.

Authors:  G Hatzidimitriou; U D McCann; G A Ricaurte
Journal:  J Neurosci       Date:  1999-06-15       Impact factor: 6.167

Review 7.  Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function.

Authors:  M Isabel Colado; Esther O'Shea; A Richard Green
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

8.  Effect of ambient temperature and a prior neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA) on the hyperthermic response of rats to a single or repeated ('binge' ingestion) low dose of MDMA.

Authors:  A Richard Green; Veronica Sanchez; Esther O'Shea; Kathryn S Saadat; J Martin Elliott; M Isabel Colado
Journal:  Psychopharmacology (Berl)       Date:  2004-01-15       Impact factor: 4.530

9.  Role of dopamine transporters in the behavioral effects of 3,4-methylenedioxymethamphetamine (MDMA) in nonhuman primates.

Authors:  William E Fantegrossi; Rayna M Bauzo; Daniel M Manvich; Jose C Morales; John R Votaw; Mark M Goodman; Leonard L Howell
Journal:  Psychopharmacology (Berl)       Date:  2009-05-07       Impact factor: 4.530

Review 10.  Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview.

Authors:  João Paulo Capela; Helena Carmo; Fernando Remião; Maria Lourdes Bastos; Andreas Meisel; Félix Carvalho
Journal:  Mol Neurobiol       Date:  2009-04-17       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.